CytomX Therapeutics Inc (CTMX, Financial) is set to release its Q1 2025 earnings on May 12, 2025. The consensus estimate for Q1 2025 revenue is $30.84 million, and the earnings are expected to come in at $0.12 per share. The full year 2025's revenue is expected to be $99.24 million, and the earnings are expected to be $0.01 per share. More detailed estimate data can be found on the Forecast page.
CytomX Therapeutics Inc (CTMX, Financial) Estimates Trends
Revenue estimates for CytomX Therapeutics Inc (CTMX) have increased from $76.27 million to $99.24 million for the full year 2025. However, for 2026, they have declined from $33.68 million to $29.24 million over the past 90 days. Earnings estimates have shown an improvement, rising from $-0.47 per share to $0.01 per share for the full year 2025. For 2026, earnings estimates have increased from $-0.77 per share to $-0.60 per share over the past 90 days.
CytomX Therapeutics Inc (CTMX, Financial) Reported History
In the previous quarter ending on December 31, 2024, CytomX Therapeutics Inc's (CTMX) actual revenue was $38.09 million, which beat analysts' revenue expectations of $19.42 million by 96.18%. CytomX Therapeutics Inc's (CTMX) actual earnings were $0.23 per share, which beat analysts' earnings expectations of $-0.20 per share by 213.86%. After releasing the results, CytomX Therapeutics Inc (CTMX) was up by 7.71% in one day.
CytomX Therapeutics Inc (CTMX, Financial) 12 Month Price Targets
Based on the one-year price targets offered by 2 analysts, the average target price for CytomX Therapeutics Inc (CTMX) is $3.75, with a high estimate of $5.00 and a low estimate of $2.50. The average target implies an upside of 244.04% from the current price of $1.09.
Based on GuruFocus estimates, the estimated GF Value for CytomX Therapeutics Inc (CTMX, Financial) in one year is $3.48, suggesting an upside of 219.27% from the current price of $1.09.
Based on the consensus recommendation from 6 brokerage firms, CytomX Therapeutics Inc's (CTMX, Financial) average brokerage recommendation is currently 2.0, indicating an "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies strong buy, and 5 denotes sell.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
